Effects of rosiglitazone on aortic function in rats with insulin resistant-hypertension

( views:, downloads: )
Author:
LING Hong-Yan()
FENG Shui-dong()
ZHOU Shou-hong()
WANG Bing-Xiang()
LIU Xian-qing()
HU Bi()
Journal Title:
ACTA PHYSIOLOGICA SINICA
Issue:
Volume 57, Issue 02, 2005
DOI:
Key Word:

Abstract:

  • [1]Wang TD, Chen W J, Lin JW, Chen MF, Lee YT. Effects of rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome in nondiabetic patients with the metabolic syndrome. Am J Cardiol 2004; 93(3): 362-365.
  • [2]Shargorodsky M, Wainstein J, Gavish D, Leibovitz E, Matas Z, Zimlichman R, Wainstein G, Ganish E, Leibovitz Z, Matas D. Treatment with rosiglitazone reduces hyperinsulinemia and improves arterial elasticity in patients with type 2 diabetes mellitus. Am J Hypertens 2003; 16(8): 617-622.
  • [3]Calnek DS, Mazzella L, Roser S, Roman J, Hart MC. Peroxisome proliferator-activated receptor γligands increase release of nitric oxide from endothelial cells. Arterioscler Thromb Vasc Biol 2003; 23: 52-57.
  • [4]Fukunaga Y, Itoh H, Doi K, Tanaka T, Yamashita J, Chun TH, Inoue M, Masatsugu K, Sawada N, Saito T, Hosoda K,Kook H, Ueda M, Nakao K. Thiazolidinediones, peroxisome proliferator-activated receptor gamma agonists, regulate endothelial cell growth and secretion of vasoactive peptides.Atherosclerosis 2001; 158(1): 113-119.
  • [5]Diep QN, Mabrouk ME1, Cohn JS, Endemann D, Amiri F,Virdis A, Neves MF, Schiffrin EL. Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin Ⅱ -infused rats: role of peroxisome proliferatoractivated receptor-γ. Circulation 2002; 105: 2296-2302.
  • [6]Iglarz M, Touyz RM, Amiri F, Lavoie MF, Diep QN, Schiffrin EL. Effect of peroxisome proliferator-activated receptor-αand -γ activators on vascular remodeling in endothelin-dependent hypertension. Arterioscler Thromb Vasc Biol 2003; 23:45-51.
  • [7]Wen JS (文金生), Hu B, Long G, Duang ZL, Ling HY, Zhou SH. Effects of rosiglitazone on blood glucose, blood lipid and vascular remodeling in rats fed with high-fructose diet. Chin Pharmacol Bull (中国药理学通报) 2004; 20(5): 571-575.(Chinese, English abstract)
  • [8]Hwang IS, Ho H, Hoffman BB, Reaven GM. Fructose induced insulin resistance and hypertension in rats. Hypertension 1987, 10: 512.
  • [9]Li GW (李光伟), Pang SR. A novel index of detecting insulin sensitivity of population. Chin J Intern Med (中华内分泌代谢杂志) 1998; 37: 390-392. (Chinese, English abstract)
  • [10]Shinozaki K, Suzuki M, Ikebuch i M, Takaki H, Hara Y,Tsushima M, Harano Y. Insulin resistance associated with compensatory hyperinsulinemia as an independent risk factor for vasospastic angina. Circulation 1995; 92: 1749-1757.
  • [11]Katakam PVG, Ujhelyi MR, Hoenig ME, Miller AW. Endothelial dysfunction precedes hypertension in diet-induced insulin resistance. Am J Physiol Regulatory Integrative Comp Physiol 1998; 275: 788-792.
  • [12]Schoonjans K, Martin G, Staels B, Auwerx J. Peroxisome proliferators-activated recepors, orphans with ligands and functions. Curr Opin Lipidol 1997; 8(3): 159-166.
  • [13]Ricote M, Huang J, Fajas L, Li A, Welch J, Najib J, Witztum JL, Auwerx J, Palinski W, Glass CK. Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma)in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. PNAS 1998; 95(13): 7614-7619.
  • [14]Walker AB, Chattington PD, Buckingham RE, Williams G.The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothe lial function in Zucker fatty rats. Diabetes 1999; 48: 1448-1453.
  • [15]Law R E, Goetze S, Xi XP, Jackson S, Kawano Y, Demer L,Fishbein MC, Meehan WP, Hsueh WA. Expression and function of PPAR in rat and human vascular smooth muscle cells.Circulation 2000; 101: 1311-1318.
  • [16]Inoue I, Shino K, Noji S, Awata T, Katayama S. Expression of peroxisome proliferator-activated receptor alpha (PPAR alpha) in primary cultures of human vascular endothelial cells.Biochem Biophys Res Commun 1998; 246(2): 370-374.
  • [17]Celermajer DS. Endothelial dysfunction: does it matter? Is it reversible? J Am Coll Cardiol 1997; 30(2): 325-333.
  • [18]Guo YM (郭益民), Zhu XN, Pan JY. Nitric oxide changes aortic function in rats with renal hypertension. Acta Physiol Sin (生理学报) 2000; 52(3): 243-246 (Chinese, English abstract).
  • [19]Dominiczak AF, Bohr DF. Nitric oxide and its putative role in hypertension. Hypertension 1995; 25: 1202-1211.
  • [20]Eto K, Ohya Y, Nakamura Y, Abe I, Fujishima M. Comparative actions of insulin sensitizers on ion channels in vascular smooth muscle. Eur J Pharmacol 2001; 423(1): 1-7.
  • [21]Cao CM (曹春梅), Ye S, Yu H, Xu QS, Ye ZG, Shen YL, Lu Y, Xia Q. Interleukin-2 induced endothelium dependent relaxation of rat thoracic aorta. Acta Physiol Sin (生理学报)2003; 55 (1): 19-23 (Chinese, English abstract).
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn